• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    4/22/24 4:31:12 PM ET
    $ALLR
    $CARA
    $CGTX
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million.
    • Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to $1.0. The market value of their outstanding shares is at $25.0 million.
    • Cognition Therapeutics (NASDAQ:CGTX) stock increased by 6.98% to $1.99. The company's market cap stands at $77.6 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares increased by 5.63% to $1.5. The company's market cap stands at $2.9 million.
    • Purple Biotech (NASDAQ:PPBT) shares moved upwards by 4.98% to $0.48. The company's market cap stands at $12.3 million.
    • Mereo BioPharma Group (NASDAQ:MREO) stock moved upwards by 4.65% to $2.92. The company's market cap stands at $409.5 million.

    Losers

    • Phio Pharma (NASDAQ:PHIO) shares declined by 7.8% to $0.76 during Monday's after-market session. The market value of their outstanding shares is at $3.5 million.
    • OptiNose (NASDAQ:OPTN) shares fell 7.09% to $0.96. The market value of their outstanding shares is at $107.8 million.
    • Portage Biotech (NASDAQ:PRTG) stock fell 7.04% to $0.28. The market value of their outstanding shares is at $5.5 million.
    • Cara Therapeutics (NASDAQ:CARA) shares declined by 6.86% to $0.68. The market value of their outstanding shares is at $37.1 million.
    • Rigel Pharmaceuticals (NASDAQ:RIGL) shares fell 6.2% to $1.06. The company's market cap stands at $185.9 million.
    • Greenwich LifeSciences (NASDAQ:GLSI) stock decreased by 5.44% to $12.0. The company's market cap stands at $154.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $CARA
    $CGTX
    $GLSI

    CompanyDatePrice TargetRatingAnalyst
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Rigel Pharmaceuticals Inc.
    $RIGL
    11/5/2025$42.00Hold → Buy
    Jefferies
    Greenwich LifeSciences Inc.
    $GLSI
    8/20/2025$45.00Outperform
    Noble Capital Markets
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    Sensei Biotherapeutics Inc.
    $SNSE
    6/2/2025$5.00Buy
    H.C. Wainwright
    Mereo BioPharma Group plc
    $MREO
    3/27/2025$7.00Overweight
    Analyst
    More analyst ratings

    $ALLR
    $CARA
    $CGTX
    $GLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mereo BioPharma downgraded by Analyst

    Analyst downgraded Mereo BioPharma from Overweight to Neutral

    3/23/26 8:27:06 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma downgraded by Jefferies with a new price target

    Jefferies downgraded Mereo BioPharma from Buy to Hold and set a new price target of $0.50

    12/30/25 7:20:11 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rigel Pharma upgraded by Jefferies with a new price target

    Jefferies upgraded Rigel Pharma from Hold to Buy and set a new price target of $42.00

    11/5/25 3:49:31 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and CFO Patel Snehal bought $53,694 worth of shares (1,800 units at $29.83), increasing direct ownership by 0.03% to 5,604,102 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/15/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $79,866 worth of shares (2,900 units at $27.54), increasing direct ownership by 0.05% to 5,602,302 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/14/26 6:05:06 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and CFO Patel Snehal bought $91,848 worth of shares (4,300 units at $21.36), increasing direct ownership by 0.08% to 5,599,402 units (SEC Form 4)

    4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

    1/5/26 6:06:39 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    SEC Filings

    View All

    Sensei Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    3/30/26 7:35:21 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events

    8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    3/30/26 7:15:34 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/27/26 4:55:30 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lankry Shai S

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/27/26 11:38:07 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Gagnon Robert E.

    3 - PURPLE BIOTECH LTD. (0001614744) (Issuer)

    3/18/26 6:06:33 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Emerson Martin J

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/18/26 4:26:10 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

    Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement supports key clinical milestones in endometrial and breast cancer Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today reported financial results for the full year ended December 31, 2025, following its previously announced acquisition of Faeth Therapeutics and concurrent $200 million private placement. The financing, together with the Company's cash on hand, is expected to support advancement of PIKTOR through key clinical milestones, including topline data readouts from both the ongoing Phase 2 trial in advanced endometrial cancer (S

    3/30/26 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

    A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous CarcinomasKing of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compound PH-762 for both clinical trial and commercial supply."It is a pleasure to partner with an organization known for its quality and ex

    3/30/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    Leadership Updates

    Live Leadership Updates

    View All

    Purple Biotech Announces CEO Transition

    Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step down from his role as CEO effective August 2026. Mr. Efron will remain actively involved with the Company, transitioning to lead corporate development and continuing as a member of the Board of Directors. In this new capacity, he will focus on identifying strategic initiatives, partnerships, and support the Company's financing activities as needed

    3/13/26 8:04:00 AM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

    PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.    Conference Call InformationTo participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webc

    3/23/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALLR
    $CARA
    $CGTX
    $GLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OptiNose Inc.

    SC 13G - OptiNose, Inc. (0001494650) (Subject)

    11/20/24 5:21:26 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Purple Biotech Ltd.

    SC 13G/A - PURPLE BIOTECH LTD. (0001614744) (Subject)

    11/14/24 5:21:29 PM ET
    $PPBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

    SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

    11/14/24 5:18:08 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care